Coya Therapeutics, Inc. Statistics
Want to see COYA full AI Analyst Report?
Coya Therapeutics, Inc. (COYA) Stock Statistics & Valuation Metrics
Total Valuation
Coya Therapeutics, Inc. has a market cap or net worth of $74.13M. The enterprise value is $81.72M.
- Market Cap
- $74.13M
- Enterprise Value
- $81.72M
Share Statistics
Coya Therapeutics, Inc. has 23,457,850 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 23,457,850
- Owned by Insiders
- 4.42%
- Owned by Institutions
- 13.46%
Financial Efficiency
Coya Therapeutics, Inc.’s return on equity (ROE) is -0.49 and return on invested capital (ROIC) is -45.98%.
- Return on Equity (ROE)
- -0.49
- Return on Assets (ROA)
- -0.42
- Return on Invested Capital (ROIC)
- -45.98%
- Return on Capital Employed (ROCE)
- -0.46
- Revenue Per Employee
- 993.22K
- Profits Per Employee
- -2.65M
- Employee Count
- 8
- Asset Turnover
- 0.16
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Coya Therapeutics, Inc. is -2.27. Coya Therapeutics, Inc.’s PEG ratio is 0.08.
- PE Ratio
- -2.27
- PS Ratio
- 15.81
- PB Ratio
- 2.21
- Price to FCF
- -3.54
- Price to Operating Cash Flow
- -3.40
- PEG Ratio
- 0.08
Income Statement
In the last 12 months, Coya Therapeutics, Inc. had revenue of 7.95M and earned -21.23M in profits. Earnings per share was -1.27.
- Revenue
- 7.95M
- Gross Profit
- 7.92M
- Operating Income
- -20.27M
- Pretax Income
- -21.22M
- Net Income
- -21.23M
- EBITDA
- -21.20M
- Earnings Per Share (EPS)
- -1.27
Cash Flow
In the last 12 months, operating cash flow was -21.83M and capital expenditures 884,997, giving a free cash flow of -20.94M billion.
- Operating Cash Flow
- -21.83M
- Free Cash Flow
- -20.94M
- Free Cash Flow per Share
- -0.89
Dividends & Yields
Coya Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -27.72%
- Earnings Yield
- -39.94%
Stock Price Statistics
- Beta
- 1.50
- 52-Week Price Change
- -46.89%
- 50-Day Moving Average
- 4.43
- 200-Day Moving Average
- 4.61
- Relative Strength Index (RSI)
- 33.69
- Average Volume (3m)
- 144.70K
Important Dates
Coya Therapeutics, Inc. upcoming earnings date is Mar 23, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 10, 2026
- Next Earnings Date
- Mar 23, 2027
- Ex-Dividend Date
- ―
Financial Position
Coya Therapeutics, Inc. as a current ratio of 8.50, with Debt / Equity ratio of 0.00%
- Current Ratio
- 8.50
- Quick Ratio
- 8.50
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 2.21
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Coya Therapeutics, Inc. has paid 3,089 in taxes.
- Income Tax
- 3,089
- Effective Tax Rate
- -0.00
Enterprise Valuation
Coya Therapeutics, Inc. EV to EBITDA ratio is -1.30, with an EV/FCF ratio of -1.90.
- EV to Sales
- 8.47
- EV to EBITDA
- -1.30
- EV to Free Cash Flow
- -1.90
- EV to Operating Cash Flow
- -1.82
Balance Sheet
Coya Therapeutics, Inc. has $35.80M in cash and marketable securities with $0.00 in debt, giving a net cash position of $35.80M billion.
- Cash & Marketable Securities
- $35.80M
- Total Debt
- $0.00
- Net Cash
- $35.80M
- Net Cash Per Share
- $1.53
- Tangible Book Value Per Share
- $1.43
Margins
Gross margin is 95.01%, with operating margin of -675.34%, and net profit margin of -643.45%.
- Gross Margin
- 95.01%
- Operating Margin
- -675.34%
- Pretax Margin
- -643.38%
- Net Profit Margin
- -643.45%
- EBITDA Margin
- -659.20%
- EBIT Margin
- -425.97%
Analyst Forecast
The average price target for Coya Therapeutics, Inc. is $15.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $15.75
- Price Target Upside
- 398.42% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 4
- Revenue Growth Forecast
- 17.59%
- EPS Growth Forecast
- -20.34%
Scores
- Smart Score
- 4
- AI Score
- 48
